CTOs on the Move

Eleven Therapeutics

www.eleventx.com

 
Eleven Therapeutics is at the forefront of mRNA therapeutics innovation, harnessing combinatorial chemistry, synthetic biology, and artificial intelligence to develop next-generation therapies. The company`s pipeline includes extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. Proprietary high-throughput screening platforms, TERA™ and DELiveri™, underpin Eleven Therapeutics` pipeline by generating chemically modified xRNAs and cell-penetrating delivery carriers. Founded in 2020 by world-leading scientists across Cambridge (UK), Boston (US), and Tel Aviv (Israel), Eleven Therapeutics is supported by top-tier venture capitalists and the Bill & Melinda Gates Foundation.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Paloma Giangrande
 Chief Technology Officer Profile

Similar Companies

Specialty Hospital Of Midwest City

Specialty Hospital Of Midwest City is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspen Medical Products

Aspen Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Interventional Systems

Terumo Interventional Systems is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarcine

Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.